🔎 Trials Near Me

Hjem › Akut bifenoypisk leukemi › Wisconsin

Kliniske studier for Akut bifenoypisk leukemi i Wisconsin

5 studier for Akut bifenoypisk leukemi søker deltakere på steder i Wisconsin.

Byer i Wisconsin

Offisiell studietekst (engelsk)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • Children's Hospital of Wisconsin, Milwaukee
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
  • og 1 flere
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

  • Children's Wisconsin, Milwaukee
Rekrutterer
Alder 0 til 25 · Alle kjønn · Oppdatert 13. mai 2026 · NCT05794880

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital of Wisconsin, Milwaukee
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.